Emergency access to two preventive options creates a new response tool for susceptible horses, while the FDA makes clear that precise use and integrated management are essential.

Emergency animal-health policy is often read as a signal to deploy a product widely. The FDA's 15 July guidance on New World screwworm prevention in horses takes the opposite approach: it provides additional tools, but only for defined risk situations and only with careful attention to safety, evidence and wound management.

The agency issued Emergency Use Authorizations for Ivermectin Liquid for Horses and for Dectomax/Dectomax-CA1 to prevent New World screwworm myiasis in horses. The authorisations are intended for horses susceptible to infestation, such as animals with injury or surgery wounds and newborn foals with a healing umbilical area. FDA explicitly says the products are not intended for healthy horses without wounds or an expectation of wounds, and neither is authorised to treat an existing infestation.

The authorised uses are deliberately specific. Ivermectin Liquid for Horses may be used for short-term prevention in newborn foals within 24 hours of birth or at the time of initial wound care in horses of any age. Dectomax/Dectomax-CA1 may be used in horses at least one year old at wound appearance or castration. FDA estimates up to 24 hours of protection after one ivermectin dose; Dectomax may protect beyond 24 hours, but the duration after that point is unknown in horses.

For equine businesses, those boundaries matter as much as the new availability. Open wounds that remain vulnerable need bandaging, fly repellents and other barrier methods in addition to either medicine. This shifts the operational focus from a single-purchase response to a managed protocol involving veterinary assessment, timing, handling and follow-up. The cost of a missed or poorly managed exposure may be high, but so is the risk of applying a medicine outside the narrow conditions for which it is authorised.

FDA is unusually direct about the evidence base. Neither product has clinical trial data in horses specifically showing prevention of New World screwworm myiasis. The EUAs meet the standard that it is reasonable to believe they may be effective under the stated conditions. For Dectomax, a dedicated horse safety study found mild adverse effects at 1.5 times the authorised dose and serious abnormalities at higher multiples, making accurate dosing especially important.

The commercial lesson is not that the emergency market is broad; it is that risk-defined readiness has value. Veterinary practices, horse owners and supply partners now need protocols that identify eligible cases rapidly and keep clinical oversight central. In a threat response, the strongest product strategy is often disciplined targeting, not indiscriminate volume.

For more information: U.S. Food and Drug Administration